Nano-carrier precision delivery to kill melanoma

Technology Daily (Reporter Mao Li) Tel Aviv University in Israel recently said that the university's research team designed a nano-carrier drug system for the treatment of skin melanoma. The researchers believe the system has the potential to expand to treat a wide range of diseases. The paper was recently published as a cover article in the journal Advanced Therapy.
nanocarbon drug system consists of biocompaly compatible and biodegradable polymers and drugs, i.e. polyglutamine (PGA) vectors and packages of two mixed drugs. The two drugs are BRAF inhibitors (darafinib) and MEK inhibitors (smetiny), which are effective in treating melanoma.Professor Ronit Shachi-Fainalo, lead researcher on the
study and head of the Department of Physiology and Pharmacology at Tel Aviv University's Sackler School of Medicine, said that biological drug treatment of cancer usually makes cancer cells resistant, but that if two or more targeted drugs can be delivered to cancer tissue accurately and powerful attacks on cancer cells in different directions, cancer cell resistance can be delayed or even prevented. Although tumors are now treated with a mixture of several drugs, they do not reach tumor tissue at the same time due to differences in basic parameters, so in most cases the drugs do not work at the same time, hindering their ability to kill cancer cells in the best possible way.
to solve these problems, they combined the two drugs to introduce the hybrid drugs into tumor tissue simultaneously through nano-vectors. Because polyglutamate makes up the nanocarbon itself biodegradable, the hybrid drugs it carries will attack cancer cells directly and simultaneously when released.
researchers tested the toxicity levels and forms of the drug and the tolerance of cancer cells to treatment to ensure maximum potency, minimal toxicity and optimal synergy.
test results in laboratory mice showed that nano-carrier drugs were not only available at lower doses, but were also safer and more effective than independent treatments using different administration methods.The next step,
researchers say, is to chemically modifie the polymer carrier to combine with the chosen hybrid drug, allowing the nano-carrier drug system to safely "travel" in the body without harming healthy tissue, but releasing an active blend of drugs to attack tumors together.